Literature DB >> 11371764

Immunopathogenesis of human T cell lymphotropic virus type I-associated myelopathy.

M Nagai1, S Jacobson.   

Abstract

Human T cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis is a chronic progressive inflammatory neurological disease. Aspects of human T cell lymphotropic virus type I biology, host genetic susceptibility, and immune responses to this agent are important factors that are associated with disease progression. The use of novel immunological and molecular methods has improved our understanding of the pathophysiological mechanisms that are operative in human T cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. Co-existing high proviral loads and virus-specific CD8 T cells are important features of this disorder, in which a high cellular immune response continuously driven by this virus may contribute to the inflammatory process within central nervous system lesions in patients with this disease.

Entities:  

Mesh:

Year:  2001        PMID: 11371764     DOI: 10.1097/00019052-200106000-00019

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  9 in total

1.  IL-10 produced by CD4+ and CD8+ T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte-derived TNF-alpha and guarantee asymptomatic clinical status during chronic HTLV-I infection.

Authors:  G E A Brito-Melo; V Peruhype-Magalhães; A Teixeira-Carvalho; E F Barbosa-Stancioli; A B F Carneiro-Proietti; B Catalan-Soares; J G Ribas; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 2.  Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP).

Authors:  Mitsuhiro Osame
Journal:  J Neurovirol       Date:  2002-10       Impact factor: 2.643

3.  Establishing phenotypic features associated with morbidity in human T-cell lymphotropic virus type 1 infection.

Authors:  G E A Brito-Melo; J G Souza; E F Barbosa-Stancioli; A B F Carneiro-Proietti; B Catalan-Soares; J G Ribas; G W Thorum; R D R Rocha; O A Martins-Filho
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

4.  Clinicopathological and virological analyses of familial human T-lymphotropic virus type I--associated polyneuropathy.

Authors:  Hirofumi Sawa; Toshiko Nagashima; Kazuo Nagashima; Toshiya Shinohara; Takayo Chuma; Yukio Mano; Nobutada Tachi; William W Hall
Journal:  J Neurovirol       Date:  2005-04       Impact factor: 2.643

5.  Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Motohiro Yukitake; Eisaburo Sueoka; Naoko Sueoka-Aragane; Akemi Sato; Hiromi Ohashi; Yusuke Yakushiji; Mineki Saito; Mitsuhiro Osame; Shuji Izumo; Yasuo Kuroda
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

Review 6.  Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy.

Authors:  Unsong Oh; Steven Jacobson
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

7.  Human T-cell lymphotropic virus in a population of pregnant women and commercial sex workers in South Western Nigeria.

Authors:  J C Forbi; A B Odetunde
Journal:  Afr Health Sci       Date:  2007-09       Impact factor: 0.927

8.  Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study.

Authors:  Jennie R Orland; Baoguang Wang; David J Wright; Catharie C Nass; George Garratty; James W Smith; Bruce Newman; Donna M Smith; Edward L Murphy
Journal:  Retrovirology       Date:  2004-03-24       Impact factor: 4.602

9.  Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers.

Authors:  Silvane Braga Santos; Aurélia Fonseca Porto; André Luiz Muniz; Amélia Ribeiro de Jesus; Elza Magalhães; Ailton Melo; Walderez O Dutra; Kenneth J Gollob; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2004-03-02       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.